Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties

ABSTRACT

Objectives: There is an epidemic of nonmedical and extra-medical use opioid abuse, addiction, and overdose. Extended-release oxycodone (OxyContin®), a prescription opioid pain reliever, was reformulated in 2010 to deter its abuse. The aim of this study was to assess changes in the onset of abuse of OxyContin and other opioids among young people and adults after reformulation of OxyContin with abuse-deterrent properties.

Methods: The study population was U.S. residents ≥ 12 years sampled in National Surveys on Drug Use and Health (NSDUH), 2004 to 2015, with subsample of 12–21-year-olds. Nonmedical and extra-medical use is the NSDUH proxy for abuse. Confidential audio-computer-assisted self-interviews were assessed. Age-specific incidence of nonmedical and extra-medical use of OxyContin and other prescription opioids were estimated year by year. Interrupted-time-series and age-period-cohort analyses were analyzed.

Results: Interrupted-time-series analysis showed a lower incidence of OxyContin nonmedical and extra-medical use after 2010 reformulation compared to the counterfactual predicted by the trend before 2010. No such difference was seen for other prescription opioids for all ages, although a lower incidence was also observed for other prescription opioids among 12–21-year-olds. Among 12–21-year-olds, a robustly lower incidence was found in 2012 compared to 2010 for OxyContin after holding constant age and cohort effects, whereas no robust difference was observed for other prescription opioids. The results showed 137,500 fewer newly incident cases of OxyContin nonmedical and extra-medical use per year.

Conclusions: This study provides evidence supporting the role of OxyContin reformulation in the reduction of onset of OxyContin nonmedical and extra-medical use.

KEYWORDS:

• Incidence
• nonmedical use
• extra-medical use
• opioid
• abuse-deterrent formulation

Acknowledgments

Medical writing and reviewing support was provided by Richa Attre.

Declaration of interest

HGC was a paid consultant to Purdue Pharma L.P. PMC was an employee of Purdue Pharma L.P. at the time of this study. Peer reviewers on this manuscript have received an honorarium from PGM for their review work, but have no other relevant financial relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed here.

Additional information

Funding

This research was supported by Purdue Pharma LP.